Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FGEN FibroGen	$7.26 -1.3%	$6.99	$4.50 ▼ $38.25	$29.31M	0.74	75,992 shs	47,684 shs
GWPH GW Pharmaceuticals	$218.96	$218.59	$87.07 ▼ $219.57	$6.86B	2.15	899,771 shs	N/A
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A
NKTR Nektar Therapeutics	$24.37 -2.9%	$13.94	$6.48 ▼ $37.38	$302.36M	0.94	499,490 shs	760,933 shs
SAGE Sage Therapeutics	$9.22 +0.1%	$7.66	$4.62 ▼ $13.47	$577.04M	0.29	1.73 million shs	2.16 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FGEN FibroGen	+18.74%	+29.17%	-4.92%	+6.06%	-67.46%
GWPH GW Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NKTR Nektar Therapeutics	+7.45%	+1.83%	+121.15%	+170.90%	+25.81%
SAGE Sage Therapeutics	+0.11%	+0.16%	+31.76%	+28.63%	-16.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FGEN FibroGen	4.6464 of 5 stars	3.3	3.0	0.0	4.7	3.8	3.3	0.6
GWPH GW Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	0.5522 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6
NKTR Nektar Therapeutics	4.8645 of 5 stars	4.4	5.0	0.0	4.2	3.7	2.5	0.0
SAGE Sage Therapeutics	3.2059 of 5 stars	2.0	2.0	0.0	4.1	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,301.36% Upside
GWPH GW Pharmaceuticals	0.00	N/A	N/A	N/A
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	251.93% Upside
SAGE Sage Therapeutics	1.94	Reduce	$8.75	-5.03% Downside

Current Analyst Ratings Breakdown

Latest FGEN, MRTX, NKTR, SAGE, and GWPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FGEN FibroGen	$29.62M	1.00	N/A	N/A	($50.89) per share	-0.14
GWPH GW Pharmaceuticals	$311.33M	22.05	$0.01 per share	18,588.22	$23.48 per share	9.33
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39
NKTR Nektar Therapeutics	$87.25M	3.57	N/A	N/A	$4.94 per share	5.08
SAGE Sage Therapeutics	$41.24M	13.98	N/A	N/A	$7.60 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
GWPH GW Pharmaceuticals	-$9.02M	-$0.24	N/A	608.22	N/A	-11.05%	-7.46%	-6.13%	N/A
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest FGEN, MRTX, NKTR, SAGE, and GWPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
GWPH GW Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FGEN FibroGen	N/A	2.02	1.98
GWPH GW Pharmaceuticals	0.01	5.13	4.31
MRTX Mirati Therapeutics	N/A	7.54	7.40
NKTR Nektar Therapeutics	N/A	3.24	3.24
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FGEN FibroGen	72.71%
GWPH GW Pharmaceuticals	81.00%
MRTX Mirati Therapeutics	N/A
NKTR Nektar Therapeutics	75.88%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
FGEN FibroGen	3.07%
GWPH GW Pharmaceuticals	3.10%
MRTX Mirati Therapeutics	3.26%
NKTR Nektar Therapeutics	5.25%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
GWPH GW Pharmaceuticals	1,161	31.35 million	N/A	Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

FGEN, MRTX, NKTR, SAGE, and GWPH Headlines

Recent News About These Companies

Sage Therapeutics (NASDAQ:SAGE) Stock Rating Lowered by Scotiabank

July 11 at 2:11 AM | americanbankingnews.com

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

July 9 at 8:16 PM | nasdaq.com

Scotiabank Downgrades Sage Therapeutics (SAGE)

July 9 at 3:48 AM | msn.com

Scotiabank Reiterates "Sector Perform" Rating for Sage Therapeutics (NASDAQ:SAGE)

July 8 at 8:40 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 8 at 3:13 AM | marketbeat.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from Analysts

July 6, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

July 4, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Shares Pass Above 50 Day Moving Average - Here's Why

July 4, 2025 | marketbeat.com

Rx Rundown: AbbVie, Healthline, Beckley Psytech and more

July 3, 2025 | mmm-online.comM

Sage’s Search for Lifeline Ran Into Defiant Biogen CEO

July 3, 2025 | biospace.comB

M&A ramped up in June, with blueBird, Sage and Snyk tie-ups

July 2, 2025 | bizjournals.com

Boston-area pharma company to lay off entire 300-person staff after sale

July 1, 2025 | msn.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)

July 1, 2025 | globenewswire.com

What Makes Sage Therapeutics (SAGE) a New Buy Stock

July 1, 2025 | zacks.com

Sage Therapeutics cuts most of its workforce following acquisition

July 1, 2025 | statnews.comS

Sage lays off entire staff of 338 amid takeover by Supernus

July 1, 2025 | fiercepharma.comF

This common kitchen herb ingredient could help target or slow Alzheimer’s

June 29, 2025 | msn.com

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

June 23, 2025 | msn.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

June 22, 2025 | msn.com

Sage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. Baird

June 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

FGEN, MRTX, NKTR, SAGE, and GWPH Company Descriptions

FibroGen NASDAQ:FGEN

$7.26 -0.10 (-1.29%)

As of 01:50 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

GW Pharmaceuticals NASDAQ:GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Nektar Therapeutics NASDAQ:NKTR

$24.37 -0.73 (-2.92%)

As of 01:50 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Sage Therapeutics NASDAQ:SAGE

$9.22 +0.01 (+0.05%)

As of 01:50 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time